Maruha Corporation

Other

H.c. Starck Gmbh

Osaka Bioscience Institute

Japan Science and Technology Corporation

H. C. Starck, Gmbh & Co Kg

Maruha Nichiro Foods, Inc.

Nobuyuki Sato

Hiroshi Oda

Yoshihiro Urade

Kosuke Seiki

Masazumi Nishikawa

Hiroshi Nakajima

Naomi Eguchi

Helmut Haas

Tadakazu Tamai

Ulrich Bartmann

Yoshio Uehara

Tadashi Komeya

Nobuaki Yatsuka

Shigeru Moriyama

Kozo Takahashi

Isao Manabe

Toshiya Ieki

Fumitaka Saji

Satoru Takeda

Teruo Inoue

Shinji Takauchi

Mitsutaka Sakamoto

Masahiko Shimada

Shoji Kimura

Masahito Matsukawa

Isami Tsuboi

Kuniharu Wada

Seiichi Ohkuma

Mitsuhito Mase

Khomei Yanagi

Yutaka Eguchi

Nobuhito Hirawa

Takashi Inui

Hiroya Nakau

Yasuhiko Shiina

Ullrich Bartmann

The present invention provides a film for forming which exhibits both excellent dimensional stability in processing and excellent formability as well as excellent appearance of surfaces and can thus be suitably applied to a variety of forming members through forming and used in forming decoration applications. Provided is a film for forming comprising a cyclic olefin-based resin as a main component, wherein the storage modulus at 120&#xb0; C. is 101 MPa to 3,000 MPa and the storage modulus at 170&#xb0; C. is 100 MPa or less.

Film for forming and forming transfer foil using same

Process for the production of valve metal powders, in particular niobium and tantalum powder, by reduction of corresponding valve metal oxide powders by means of vaporous reducing metals and/or hydrides thereof, preferably in the presence of an inert carrier gas, wherein the reduction is performed at a vapor partial pressure of the reducing metal/metal hydride of 5 to 110 hPa and an overall pressure of less than 1000 hPa, and tantalum powder obtainable in this way having a high stability of the powder agglomerate particles.

Method for production of niobium and tantalum powder

Nucleic acid sequences coding for the chondroitinase ABC gene and isolated chondroitinase ABE protein produced in a host cell transformed with a nucleic acid vector directing the expression of a nucleotide sequence coding for chondroitinase ABE protein described. Chondroitinase ABC prepared by chemical synthesis also described. Monoclonal and polyclonal antibodies which are specifically reactive with chondroitinase ABC protein are disclosed. The isolated chondroitinase ABC can be used in methods of treating intervertebral disc replacement, promoting neurite regeneration, and detecting galactosaminoglycans.

Gene encoding chondroitinase ABC and uses therefor

Method for the production of niobium and tantalum powder

Provided are: a method for predicting the onset of pregnancy-induced hypertension (PIH) by precisely detecting abnormalities that occur before the onset of PIH (where such abnormalities have been impossible to detect by various conventional testing methods for PIH) while imposing less of a burden on a subject; a method for evaluating a fetus and placental functions in PIH; and a method for detecting PIH, which comprises measuring the level of human lipocalin-type prostaglandin D synthase (L-PGDS) in a body fluid sample collected from a subject.

Method for predicting pregnancy-induced hypertension

The present invention relates to methods for differentiating demential diseases comprising measuring the concentration of human lipocalin-type prostaglandin D synthase in a sample of a body fluid collected from a subject and kits for differentiating demential diseases comprising an antibody specific to human lipocalin-type prostaglandin D synthase.

Methods to facilitate diagnosis of normal pressure hydrocephalus

The present invention relates to a method of detection of an early-stage renal disease, comprising determining the concentration of human lipocalin-type prostaglandin D synthase in a body fluid sample taken from a subject and comparing the determined concentration with a reference value set by determining the concentrations of human lipocalin-type prostaglandin D synthase in body fluid samples taken from healthy subjects; and a method of disease state management for a renal disease, comprising determining the concentration of human lipocalin-type prostaglandin D synthase in a body fluid sample taken from a subject and evaluating the glomerular filtration ability of the subject from the determined concentration.

Method of detection and disease state management for renal diseases

Sebum production inhibitors containing as an active ingredient a compound of general formula (1) below having a glucuronic acid derivative and a glucosamine derivative in the structure or a pharmacologically acceptable salt thereof

Sebum production inhibitors

The present invention provides a method for predicting restenosis following coronary intervention by measuring human lipocalin-type prostaglandin D synthase (L-PGDS) in a body fluid sample. More particularly, this method comprises measuring the L-PGDS concentration in the sample and predicting restenosis following coronary intervention by using a change therein as an indicator.

Method for restenosis following coronary vessel intervention

{circle around (1)} Compounds of the following general formula (1) having a glucuronic acid derivative and a glucosamine derivative in the structure thereof, pharmacologically acceptable salts and solvates of the compounds, or solvates of the salts, {circle around (2)} a method for producing the compounds {circle around (1)}, {circle around (3)} a pharmaceutical composition containing the compounds {circle around (1)}, {circle around (4)} polymers having at least one of the compounds {circle around (1)} as a side chain structure, {circle around (5)} a coating agent containing the compound {circle around (1)} or the polymer as one of active ingredients, and {circle around (6)} molded products, artificial organs, medical devices, and equipment for cell culture, which have been produced using the polymer {circle around (4)} and/or the coating agent {circle around (5)}.

Compounds having glucuronic acid derivatives and glucosamine derivative in the structure, process for producing the same and utilization thereof

The invention relates to a monoclonal antibody specifically recognizing lipocalin-type prostaglandin D synthase (L-PGDS), a hybridoma producing the monoclonal antibody, methods for detection of L-PGDS or diseases by the monoclonal antibody, and a kit for detection of L-PGDS by the monoclonal antibody. According to the invention, there is provided a monoclonal antibody specific to L-PGDS.

Prostaglandin D synthase-specific monoclonal antibody

The present invention provides a method for detecting or predicting ischemic disorders in a subject by using as an indication the concentration of human lipocalin-type prostaglandin D synthase (hPGDS) in body fluid samples from the subject. More specifically, the method comprises comparing the hPGDS concentrations in the body fluid samples from a subject with the reference values established for a normal subject, thereby detecting or predicting the ischemic disorders.

Methods and kits for detecting or predicting ischemic disorders

Disclosed are two lectin species isolated from the hemolymph of Japanese horseshoe crabs and Southern horseshoe crabs which bind to N-acetylneuraminic acid and N-glycolylneuraminic acid, but not to N-acetylglucosamine, glucoronic acid, or N-acetylgalactosamine.

Lectin species obtained from Japanese horseshoe crabs and from southern

Growing community of inventors

Ibaraki, Japan

Nobuyuki Sato